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RegulationThe post-translational attachment of one or several ubiquitin molecules to a protein generates a variety of
targeting signals that are used in many different ways in the cell. Ubiquitination can alter the activity, local-
ization, protein–protein interactions or stability of the targeted protein. Further, a very large number of pro-
teins are subject to regulation by ubiquitin-dependent processes, meaning that virtually all cellular functions
are impacted by these pathways. Nearly a hundred enzymes from ﬁve different gene families (the
deubiquitinating enzymes or DUBs), reverse this modiﬁcation by hydrolyzing the (iso)peptide bond tether-
ing ubiquitin to itself or the target protein. Four of these families are thiol proteases and one is a
metalloprotease. DUBs of the Ubiquitin C-terminal Hydrolase (UCH) family act on small molecule adducts
of ubiquitin, process the ubiquitin proprotein, and trim ubiquitin from the distal end of a polyubiquitin
chain. Ubiquitin Speciﬁc Proteases (USPs) tend to recognize and encounter their substrates by interaction
of the variable regions of their sequence with the substrate protein directly, or with scaffolds or substrate
adapters in multiprotein complexes. Ovarian Tumor (OTU) domain DUBs show remarkable speciﬁcity for dif-
ferent Ub chain linkages and may have evolved to recognize substrates on the basis of those linkages. The
Josephin family of DUBs may specialize in distinguishing between polyubiquitin chains of different lengths.
Finally, the JAB1/MPN+/MOV34 (JAMM) domain metalloproteases cleave the isopeptide bond near the at-
tachment point of polyubiquitin and substrate, as well as being highly speciﬁc for the K63 poly-Ub linkage.
These DUBs regulate proteolysis by: directly interacting with and co-regulating E3 ligases; altering the
level of substrate ubiquitination; hydrolyzing or remodeling ubiquitinated and poly-ubiquitinated sub-
strates; acting in speciﬁc locations in the cell and altering the localization of the target protein; and acting
on proteasome bound substrates to facilitate or inhibit proteolysis. Thus, the scope and regulation of the
ubiquitin pathway is very similar to that of phosphorylation, with the DUBs serving the same functions as
the phosphatase. This article is part of a Special Issue entitled: Ubiquitin–Proteasome System. Guest Editors:
Thomas Sommer and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ubiquitin (Ub) is a highly conserved 76-residue protein present in
all eukaryotic cells. Through a series of enzymatic reactions, the
C-terminus of Ub becomes activated and conjugated to the ε-amino
groupof lysine or theN-terminalα-amino group of another Ub, forming
poly-Ub chains, or conjugated to target proteins to form a ubiquitinated
protein [1]. The conjugation pathway begins with an E1 activating en-
zyme that uses ATP to ﬁrst adenylate Ub's C-terminal carboxylate and
transfer it to an E2 conjugating enzyme (~35 in humans) forming an
E2-Ub thioester intermediate (E2 ~ Ub) [2,3]. E3 Ub ligases (N500 puta-
tive E3s in humans) provide substrate speciﬁcitywithin the conjugation
pathway by selectively binding both E2 ~ Ub and the target protein to
catalyze the transfer of Ub to a lysine or α-amino group of the target
protein. E3s fall into two general categories, RING domain E3s (Reallytin–Proteasome System. Guest
04 727 0412; fax: +1 404 727
n).
l rights reserved.Interesting New Gene) which catalyze direct transfer of the E2 ~ Ub to
a lysine group within substrate/Ub, and HECT (homologous to E6AP
Carboxyl-terminus) domain or RBR (RING-between-RING) E3s which
contain active site thiols and form an additional E3 ~ Ub thioester inter-
mediate prior to ligation onto Ub/substrate [1,4–6].
Ubiquitination can generate many different types of covalent modi-
ﬁcations [7]. The conjugation of a single Ub to a protein amino group is
called mono-ubiquitination. This modiﬁcation was ﬁrst described when
the chromosomal protein A24 was identiﬁed as histone H2A mono-
ubiquitinated at K119 [8]. This histone modiﬁcation is an epigenetic
mark that regulates chromosome structure and transcription [9], while
mono-ubiquitination of many cell surface receptors is used as a sorting
signal to direct these endocytosed proteins to lysosomal degradation
[10]. Poly-Ub chains can be assembled when additional ubiquitins are
conjugated to the protein-bound monoubiquitin using any of the
seven lysines within Ub or the N-terminal α-amino group (forming lin-
ear poly-Ub). Thus, ubiquitination of proteins can result in many struc-
turally unique polymers that direct the modiﬁed proteins to different
fates. Proteins modiﬁed with poly-Ub chains linked through K48 or
K11 of Ub are recognized and degraded by the 26S proteasome, while
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signal transduction, lysosome-directed protein sorting and the DNA
damage response [10–14]. Linear poly-Ub is assembled during inﬂam-
matory signaling [15,16]. Thus, Ub is a post-translational modiﬁcation
similar to phosphorylation or glycosylation and regulates the stability,
localization, or activity of modiﬁed proteins. DUBs play a role very sim-
ilar to that of the phosphatases in kinase/phosphatase pathways.
It is worth noting that this system of modiﬁcation is so useful to
the cell that several other Ub-like proteins have evolved. Thus,
Ub-like proteins such as Nedd8, SUMO, and others undergo virtually
identical activation and conjugation reactions to modify a large num-
ber of proteins [17,18]. A separate family of DUBs containing the ULP
(Ubiquitin-like protease) domain exhibit speciﬁcity for SUMOylated
proteins [19]. This review will concentrate on Ub-dependent process-
es but will brieﬂy mention Nedd8 modiﬁcations since it is required
for optimal activity of one family of E3 ligases.
Like all regulatory post-translational modiﬁcations, ubiquitination is
reversible. A class of proteases called deubiquitinating enzymes (DUBs)
removes Ub from target proteins and disassembles polyubiquitin chains
[20,21]. Deubiquitination is the process of hydrolyzing the (iso)peptide
bond linking Ub to a substrate or to itself in a poly-Ub chain. Most often
the bond hydrolyzed is an isopeptide linkage between a lysine ε-amino
group and the C-terminal carboxylate of Ub. Some DUBs display speci-
ﬁcity toward different chain linkages, such as K48 or K63 poly-Ub,
while some act less speciﬁcally and are capable of cleaving multiple
chain types or even Ub-like modiﬁers [20]. Like many other proteases,
DUBs are often inactive or autoinhibited, remaining inactive until they
are recruited to their site of activity or bind to the proper substrates.
To achieve proper localization and speciﬁcity DUBs aremodular, requir-
ing domains outside the catalytic core to associate with scaffolds, sub-
strate adapters, or the substrates themselves [20].
This reviewwill discuss several of these deubiquitinating enzymes
and highlight a number of ways in which they can regulate proteoly-
sis and other Ub-dependent processes (Fig. 1). It is not comprehen-
sive, but only exemplary of the different modes of action observed
to date. We will concentrate on those DUBs that have been extensive-
ly characterized, where structures are known, and where their mech-
anisms of action highlight different aspects of cellular regulatory
strategies.2. The ﬁve families of deubiquitinating enzymes
An early bioinformatics approach identiﬁed 95 putative DUBs in
the human genome [22], yet several lack an active site cysteine or
have been shown to act on Ub-like protein conjugates. A more recent
estimate puts the number of human ubiquitin-speciﬁc DUBs at 86
[23]. DUBs can be grouped into ﬁve families based on their conservedFig. 1. A given substrate (S) can exist in the free state or bound in a complex (C), each locat
the free (black line) or ubiquitinated (green line) substrate. Depending on the value of thes
protein can be directly bound by the proteasome (red line) or shuttled to the proteasome (catalytic domains. Four of these families are thiol proteases and com-
prise the bulk of DUBs, while the ﬁfth family is a small group of Ub
speciﬁc metalloproteases (see below).
2.1. Thiol protease DUBs
Most DUBs are thiol proteases that utilize a catalytic mechanism
analogous to that of the plant cysteine protease papain [24,25].
Thiol-containing DUBs contain a Cys-His-Asp/Asn catalytic triad in
which the Asp/Asn functions to polarize and orient the His, while the
His serves as a general acid/base by both priming the catalytic Cys for
nucleophilic attack on the (iso)peptide carbonyl carbon and by donat-
ing a proton to the lysine ε-amino leaving group. The nucleophilic at-
tack of the catalytic Cys on the carbonyl carbon produces a negatively
charged transition state that is stabilized by an oxyanion hole composed
of hydrogen bond donors. A Cys-carbonyl acyl intermediate ensues and
is then hydrolyzed by nucleophilic attack of awatermolecule to liberate
a protein C-terminal carboxylate and regenerate the enzyme. A striking
feature of the thiol protease DUBs is that despite divergent tertiary
folds, crystal structures in complex with Ub have revealed the positions
of the catalytic dyad/triad discussed above are nearly superimposable
[21,26]. Upon bindingUb, the catalytic domains often undergo structur-
al rearrangements to order regions involved in catalysis. Recently it has
been found thatmany DUBs are inactivated by oxidation of the catalytic
cysteine to sulphenic acid (\SOH) [27–29]. The sulphenic acid can be
further oxidized to generate sulphinic acid (\SO2H), sulphonic acid
(\SO3H), a disulﬁde, or a sulphenyl amide, which occurs when a
sulphenic acid reacts with a nearby backbone amide. Like the disulﬁde
bond, the suphenic acid and sulphenyl amide forms can be reduced
with DTT or glutathione.
The thiol proteases are reversibly inhibited by Ub C-terminal alde-
hyde, forming a thio-hemiacetal between the aldehyde group and the
active site thiol. They are irreversibly inactivated by alkylation or ox-
idation of the catalytic cysteine or reaction of the active site thiol on
Ub derivatives containing electrophilic groups near the C-terminus
of Ub (i.e., Ub-vinylsulfone, -vinylmethyl ester, -chloroethylamine,
and more recently -propargylamine)[30–34].
2.1.1. Ub C-terminal Hydrolase (UCH) domain
DUBs of the UCH family are thiol proteases that contain an
N-terminal, 230-residue catalytic domain, sometimes followed by
C-terminal extensions that mediate protein-protein interactions. In
humans there are four UCH DUBs (UCH-L1, UCH-L3, UCH37/UCH-L5,
and BAP1) and these can be sub-grouped based on their substrate
speciﬁcity. The smaller UCH DUBs (UCH-L1 and UCH-L3) prefer cleaving
small leaving groups from the C-terminus of ubiquitin, while the larger
UCH DUBs (UCH37 and BAP1) can disassemble poly-Ub chains.ion containing its own distinct E3 and DUB. The strength of binding can be different for
e binding constants, ubiquitination can either recruit or release S from C. Ubiquitinated
dashed blue line) if C is a ubiquitin receptor.
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and are capable of cleaving small molecules and amino acids linked
by ester, thioester and peptide bonds to the C-terminus of Ub, yet
they are inactive towards di-Ub [35]. In contrast, BAP1 and UCH37
are capable of acting on di-Ub and poly-Ub chains [36–38]. The
basis of this speciﬁcity stems from a loop that crosses over the UCH
catalytic site, forming a pore through which the C-terminus of Ub
must be threaded. The length of this crossover loop, and hence the di-
ameter of the pore, varies amongst the enzymes. Engineered UCH-L1
and UCH-L3 are able to cleave di-Ub only when insertions extend
these loops [39,40]. Conversely when the UCH37 loop is shortened
by 3-6 amino acids it can no longer cleave di-Ub [39].
In addition to longer crossover loops, UCH37 and BAP1 have
C-terminal extensions of ~100 and ~500 residues respectively. In
UCH37, the C-terminal extension mediates association with Adrm1/
Rpn13 of the proteasomal 19S regulatory subunit and with NFRKB of
the INO80 chromatin remodeling complex [41–44]. When associated
with the proteasome, UCH37 disassembles poly-Ub chains by hydrolyz-
ing the distal ubiquitin from a chain [38] (see Fig. 2A for proximal/distal
nomenclature). The extreme C-terminal segment of BAP1 is 38% identi-
cal to the C-terminus of UCH37 (deﬁning the UCH37-like domain, ULD)
and is necessary for binding the YY1 transcription factor and BRCA1
[45,46]. The N-terminal portion of the BAP1 extension shares little ho-
mology to other proteins, but binds BARD1 and the transcriptional reg-
ulator HCF-1 [36,37,47].2.1.2. Ub-speciﬁc processing protease (USP) domain
USPs constitute the largest of the DUB families; there are ~56 USP
members in humans and 16 in yeast. The USP catalytic domain can
vary considerably in size, between 295 and 850 residues, and consists
of six conserved motifs with N- or C-terminal extensions and insertionsFig. 2. Ubiquitin binding sites within deubiquitinating enzymes. (A) Di-ubiquitin is depicte
ubiquitin is the initial ubiquitin within a chain, while the distal ubiquitin is ﬁnal ubiquitin wi
chain, or contains a free C-terminal carboxylate in an unanchored chain. (B) A general scena
clature used to describe ubiquitin binding sites within DUBs stems from work on the serine
active site must contact residues ﬂanking the scissile bond, and the S1 and S1′ sites are attr
spectively. The S1 site binds the ubiquitin containing carboxylate of the hydrolyzed (iso)pep
Thus S1 site binds to the distal ubiquitin within a chain, and the S1′ site binds the proximal
catalytic domain or S1′ can reside within the catalytic domain. (C) IsoT/USP5 has four ubiqu
which, in this case, are formed by two UBA domains that are inserted within the catalytic U
ZnF-UBP domain forms direct interactions with the ubiquitin C-terminal carboxylate.occurring between the conserved motifs [23]. Two highly conserved re-
gions comprise the catalytic triad, the Cys-box (Cys) and His-box (His
and Asp/Asn) [22,23,48]. These DUBs tend to recognize and encounter
their substrates by interaction of the variable regions of sequence with the
substrate protein directly, or with scaffolds or substrate adapters in
multiprotein complexes.
The ﬁrst USP structure described, that of USP7, revealed three
subdomains that resemble the thumb, palm and ﬁngers of a right
hand [49]. The cleft formed between the palm and the thumb forms
the catalytic center, with the thumb containing the Cys-box and the
palm the His-box. The ﬁnger subdomain forms interactions with Ub to
position its C-terminus within the catalytic center. The structure of
USP5/IsoT shows how 2 UBL domains inserted within a USP domain
provide additional Ub binding sites that allow the enzyme to bind and
disassemble poly-Ub chains [50]. The apo structure of USP7 showed a
misaligned catalytic triad, yet when complexed with Ub-aldehyde,
USP7 undergoes conformational changes within the catalytic cleft, in-
cludingmovement of the catalytic Cys andHis residues [49]. In contrast,
the structure of USP14, with and without Ub-aldehyde, revealed a
well-aligned catalytic triad but two surface loops that occlude the active
site in the apo formare displaced uponUb-aldehyde binding [51]. Could
the active site geometry of unbound DUBs reﬂect a tendency for their
oxidation, which requires deprotonation of the catalytic Cys? The
USP7 enzyme showed enhanced activity in the presence of DTT, howev-
er the USP14 enzyme with its prealigned catalytic triad was inactive,
even after addition of DTT, suggesting its catalytic Cys is readily oxidized
to the sulphinic/sulphonic acid form [27].2.1.3. Ovarian tumor (OTU) domain
Interest in the Drosophila ovarian tumor gene OTU sparked a bioin-
formatics search that identiﬁed several OTU homologs in eukaryotesd to exemplify the proximal ubiquitin (Ub1) and distal ubiquitin (Ub2). The proximal
thin a chain. The proximal ubiquitin is tethered to the substrate in an anchored poly-Ub
rio depicting a thiol DUB catalyzing the hydrolysis of a di-ubiquitin chain. The nomen-
protease papain and its recognition sites for peptide substrates. Like papain, the DUB
ibuted to the acyl-intermediate side and the leaving group side of the scissile bond re-
tide bond, and the S1′ site binds the ubiquitin containing the amine of the peptide bond.
ubiquitin. It should be noted the S1′ site in DUBs can be formed by residues outside the
itin binding sites. IsoT/USP5 is one example of a DUB containing S2 and S3 binding sites
SP domain. IsoT/USP5 cannot hydrolyze substrate-anchored poly-Ub as its N-terminal
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novel family of cysteine protease DUBs [52]. Shortly thereafter OTUB1
and OTUB2 were isolated from HeLa cells and shown to cleave
isopeptide linked Ub [53]. In humans there are 15 OTU DUBs that can
be evolutionally divided into three classes, the OTUs, the Otubains
(OTUBs), and the A20-like OTUs [21].
Members of the OTU DUB family display remarkable speciﬁcity for
different poly-Ub chain linkages. OTUB1 is highly speciﬁc for
K48-linked chains, even in mixed chain linkages, whereas OTUB2 can
cleave both K63 and K48-linked poly-Ub [54,55]. The A20 enzyme is
speciﬁc for K48-linked chains, Cezanne prefers K11-linked chains, and
TRABID acts on bothK29 andK33-linkedpoly-Ub [56–58]. Crystal struc-
tures of the human OTUB1, OTUB2, TRABID, A20, and yeast Otu1 en-
zymes have revealed the conserved catalytic OTU domain which
contains the S1 site, and N-terminal residues in TRABID and OTUB1
that form the S1′ site [55–57,59–61] (see Fig. 2B S1/S1′ nomenclature).
The active site of the OTU domain contains an unusual loop not seen in
other thiol-DUBs and can lack an obvious catalytic Asp/Asn [57,60,61].
In OTUB1, Ub-aldehyde binding to the S1 active site induces structural
rearrangements at the S1′ site, suggesting only K48 poly-Ub linkages
productively engage both sites yielding a positioning of the isopeptide
bond that permits catalysis [54]. The A20 and OTUB1 enzymes have
displayed unusual modes of activity (discussed in later sections) as
they directly bind to E2 enzymes [62,63]. OTU DUBs show remarkable
speciﬁcity for different Ub chain linkages and may recognize substrates
on the basis of those linkages.2.1.4. Josephin domain
In humans there are four proteins that contain the ~180 residue
Josephin domain (Ataxin-3, Ataxin-3L, Josephin-1 and Josephin-2)
and all have been shown to possess DUB activity, though to different
extents, towards Ub-AMC, Ub-peptide fusions, and K48 poly-Ub or
K63 poly-Ub [64,65]. Ataxin-3 and -3L contain C-terminal extensions
composed of two tandem UIMs (Ub-interacting motif), a poly-Gln
stretch, and an additional UIM in ataxin-3. The UIMs in Ataxin-3
have been shown to promote Ub-binding, its ubiquitination, and its
K63 chains speciﬁcity [66–68].
Ataxin-3 is the best studied of the Josephin familymembers as an ex-
pansion of its poly-glutamine stretch gives rise to the neurodegenerative
disorder Machado-Joseph disease (also known as spinocerebellar ataxia
type 3) [69]. Attempts to gain insights into Ataxin-3 function led to a
bioinformatifcs study that predicted Ataxin-3 was a cysteine protease
DUB [70]. Shortly thereafter this was conﬁrmed when Ataxin-3 was
shown to bind long K48 poly-Ub chains and trim Ub from poly-
ubiquitinated lysozyme, an activity inhibited by Ub-aldehyde [71]. Anal-
ysis of Ataxin-3 substrate speciﬁcity found it can bind longer K63 and
K48poly-Ub (≥5), but its activity is highly speciﬁc towards K63 linkages
in homogenous and mixed chains [66]. Thus, the Josephin domain DUBs
may specialize in distinguishing between polyubiquitin chains of different
lengths.
The solution structures of the Ataxin-3 Josephin domain, alone and
in complexwithUb, and a crystal structure of theAtaxin-3L Josephin do-
main covalently bound to Ub-chloroethylamine have been reported
[64,67,72]. The two Josephin domains are 85% identical, and adopt a
similar overall fold, yet the binding site for Ub is quite different between
the two [64] (Fig. 3). Differences are also observed in the C-terminus of
bound Ub; in the crystal structurewith covalently boundUb the catalyt-
ic Cys-His-Asn triad is aligned, whereas in the solution structure the
C-terminus of Ub splits the catalytic Cys and His yielding a non-
productive catalytic conformation. The distorted triad could be a charac-
teristic of a product complex, since the product Ub contains a C-terminal
carboxylate not present in a poly-Ub substrate. Finally, the solution
structure shows a second free Ub bound to the opposite face of the
Josephin domain (S2 site) with its C-terminus positioned towards K48
of Ub bound in the active site. This could represent yet another Ubbinding site (in addition to the catalytic site and UIM sites) capable of
binding K48-linked polyubiquitin.
2.2. Metalloprotease DUBs
Sequence alignments within the JAMM domain identiﬁed a Glu-x
[N]-His-x-His-x[10]-Asp motif Zn2+ binding sites [73,74] and soon
thereafter the RPN11 subunit of the proteasome was shown to possess
DUB activity dependent on these coordinating residues and a bound
Zn2+ atom [75,76]. The JAMMdomain is present in bacterial and archae-
al proteins as well [73], and crystal structures of the AF2198 JAMM pro-
tein from Archaeoglobus fulgidus revealed that the domain adopts a fold
most similar to the metallohydrolase cytidine deaminase, while the ar-
rangement of Zn2+ ligands is most similar to the metalloprotease
thermolysin [74,77]. Catalysis requires nucleophilic attack on the car-
bonyl carbon of the isopeptide bond by an activated water molecule
bound to Zn2+ and a conserved glutamate. A negatively charged tetra-
hedral transition state ensues, and a nearby conserved Ser/Thr in the
JAMM domains stabilizes the oxyanion. The tetrahedral intermediate
then collapses and the Glu serves as a general base donating a proton
to the leaving Lys side chain [77,78]. Metallo DUBs are insensitive to
alkylating agents, Ub aldehyde, or Ub-electrophiles but can be inhibited by
removing the catalytic zinc.
2.2.1. The JAB1/MPN+/MOV34 (JAMM) domain
The JAMMdomain is found in eight human proteins, however PRPF8
is predicted to lack protease activity [21]. Two multisubunit complexes,
the proteasome 19S lid complex and the COP9-Signalosome contain
JAMM DUBs (POH1/hRpn11 and CSN5/Jab1 respectively). As discussed
later, RPN11 is an endopeptidase that cleaves poly-Ub chains en bloc
from substrates as they are degraded by the proteasome [75,76].
CSN5/Jab1 deconjugates theUb-likemodiﬁerNedd8 tomodulate the ac-
tivity of the SCF E3 ligase [79]. The roles of BRCC36 in the DNA damage
response and AMSH in endocytic trafﬁcking are discussed in later sec-
tions. An emerging theme of JAMM domains is that they function by cleav-
ing at the base of the chain, between proximal Ub and substrate (RPN11,
CSN5/Jab1), and/or they are highly speciﬁc for K63 poly-Ub linkages
(RPN11, AMSH, AMSH-LP, BRCC36) [75,79–82]. To date there are 3 crystal
structures of human JAMM domains; CSN5/JAB1 [83], AMSH [84], and
AMSH-LP in complex with K63 di-Ub, which has yielded insights into
K63 poly-Ub speciﬁcity [82].
3. How do DUBs regulate Ub-dependent processes?
It is nowwidely understood that ubiquitination generates a targeting
signal that can be used to alter the properties or localization of the
ubiquitinated protein. The ﬁrst discovered, and perhaps still most prom-
inent, role for ubiquitination is in delivering ubiquitinated proteins to the
proteasome, a large compartmentalized multi-catalytic protease that is
responsible for much of the regulated proteolysis in cells [85,86]. We
can use this system as an analogy for all Ub-dependent processes. Fig. 1
represents a generalmodel for regulatingUbdependent processes. Apro-
tein can exist in a ubiquitinated or deubiquitinated form interconverted
by the action of an E3 and a DUB. In principal, the ubiquitination state
can alter the activity of the target protein, its localization (by altering
the stability of a protein complex such as Ub-S in complex 1) or its
half-life (by delivering it to the proteasome). Furthermore, each location
can contain a different set of E3s and DUBs leading to location speciﬁc
ubiquitination or deubiquitination.
Given this very general model, we can predict several modes of
regulation by DUBs. DUBs can act by: directly interacting with and
co-regulating E3 ligases; altering the level ubiquitination; hydrolyzing
or remodeling ubiquitinated and poly-ubiquitinated substrates; by act-
ing only in certain locations in the cell and altering the localization of
the target protein; or by acting at the proteasome itself to facilitate or in-
hibit proteolysis.
Fig. 3. The Josephin domain (JD) contains multiple ubiquitin binding sites. (A) NMR solution structure of the Ataxin-3 Josephin domain with residues of the catalytic triad shown as
spheres (PDB 2AGA). (B) An independent NMR solution structure showing a similar fold with the exception of helices α2 and α3 which adopt an alternative conformation (PDB
1YZB). (C) Solution structure of Ataxin-3 JD non-covalently associated with two ubiquitin molecules (PDB 2JRI). One ubiquitin is bound at the S1 site and its C-terminal tail bisects
the catalytic Cys-His pair, possibly a reﬂection of the product complex that follows hydrolysis of the isopeptide bond. A second ubiquitin is bound at the S2 site of the Josephin do-
main, and its C-terminus is juxtaposed with K48 of ubiquitin bound at the S1 site. (D) Crystal structure of the Ataxin-3L JD covalently bound to Ub-chloroethylamine (PDB 3O65).
This structure reveals the Ataxin-3L JD binds ubiquitin at the S1 site using different residues and positions ubiquitin in an alternate conformation.
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It has been noted that many DUBs exist in complexes with E3 li-
gases and regulate the accumulation of ubiquitinated substrates.
Well-known DUB/E3 pairs are; Usp2a and Usp7/Mdm2, Usp7/ICP0,
Usp8/Ndrp1 and GRAIL, Usp20 and Usp33/VHL, and Ataxin-3/Parkin
[87]. In principle, the DUBs could act catalytically to deubiquitinate
the E3 or the substrate, and could also have non-catalytic effects by
altering the stability or composition of the E3 complex. While there
are numerous examples of this type of regulation we have chosen
just three, in part because each also has other modes of regulation
that we highlight. The examples chosen here emphasize that a
given DUB can have more than one mode of action with respect to a
single substrate and can participate in the regulation of several differ-
ent substrates.3.1.1. A deneddylating DUB activity is required for optimal SCF E3 activity
The catalytic activity of the Skp, cullin, F-box (SCF) family of E3 ligases
is highly dependent on a DUB, albeit one acting on the cullin subunit of
this ligase conjugated to the Ub-like protein Nedd8. This DUB activity is
contributed by the CSN5 subunit (a JAMM domain DUB) of the eight
subunit COP9 Signalosome (CSN) [79,88]. Its activity is required for SCF
catalytic activity and the cyclical NEDDylation and deNEDDylation of
Cullins is required for optimal SCF activity [89]. CSN is involved in multi-
ple cellular pathways, such as cell cycle control, transcriptional regula-
tion, and the DNA damage response, and the CSN5/Jab1 subunit can
function in non-CSN complexes [90]. This pathway of modiﬁcation has
recently been implicated in a variety of cancers and an inhibitor of
Nedd8 activating enzyme is in clinical trials [91,92].3.1.2. DUBs acting to deubiquitinate E3s
A characteristic hallmark of the E3mechanism is autoubiquitination.
In the absence of substrates many (most?) E3s ubiquitinate themselves
and are then subject to degradation by the proteasome. Alternatively,
these ligases can be ubiquitinated by other E3s to regulate their degra-
dation. DUBs present in the same protein complexes can reverse these
ubiquitination events, sparing the E3 so that it can respond to increases
in substrate. For example, USP7 deubiquitinates autoubiquitinated
Mdm2, the p53 Ub ligase (see below). USP7 also deubiquitinates
autoubiquitinated RING2 ligase of the polycomb complex and RING2
that has been marked for degradation by the E6AP ligase.3.1.3. E3/DUB co-regulation by reciprocal ubiquitination/deubiquitination
of a substrate
A large number of DUBs have been shown to hydrolyze protein
bound K48-linked polyubiquitin chains and prevent the degradation
of the attached proteins. Two illustrative examples are discussed
here.3.1.3.1. USP7. USP7 is a versatile DUB,with an ever expanding list of sub-
strates that are involved in various cellular pathways (see Table 1) [93].
USP7 is also a key regulator of the p53 tumor suppressor, a sequence
speciﬁc transcription factor that becomes activatedupon various cellular
stresses and elicits according cellular responses such as cell cycle arrest,
DNA repair, apoptosis and senescence [94]. The cellular level and activity
of p53 are tightly regulated, in part by an E3 ligase Mdm2 which binds
the p53 transactivation domain inhibiting activation, shuttles nuclear
p53 into the cytoplasm where it is inactive, and ubiquitinates p53 pro-
moting its degradation [95]. USP7 is critical component of this pathway
as it deubiquitinates and stabilizes both p53 and Mdm2; reduction of
USP7 levels destabilizes p53 by promoting the ubiquitinated form, yet
ablation of USP7 increases p53 levels by destabilizing Mdm2 [96,97].
The levels of p53 are also regulated by Mdmx, a structural homolog
Mdm2 that lacks E3 activity, but binds p53 and prevent ubiquitination
anddegradation byMdm2. Like p53,Mdmx is co-regulated by reciprocal
ubiquitination/deubiquitination by Mdm2/USP7 [98].3.1.3.2. OTUB1. DUBs that deubiquitinate proteasomal substrates should
exhibit signiﬁcant activity on K48-linked chains. OTUB1 has been
shown to stabilize substrates by catalytic and non-catalytic mecha-
nisms. It has deubiquitinating activity and exhibits high speciﬁcity for
K48 isopeptide linkages, even in mixed linkage chains [54,55]. OTUB1
and its paralog OTUB2, deubiquitinate TRAF3 and TRAF6 to inhibit
virus-triggered signaling pathways that ultimately result in IRF3 and
NF-κB activation [99]. OTUB1 has also been shown to stabilize the estro-
gen receptor α [100] and RhoA [101] and in both cases stabilization is
dependent on OTUB1's catalytic Cys91.3.1.4. Modulation of E2 activity
In principle, DUBS could interfere with Ub activation, formation of
the E2 ~ Ub intermediate, or reactivity of the intermediate to inhibit
ubiquitination. Two examples of the later mechanism are discussed;
one catalytic and one non-catalytic.
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modulating E2 activity is afforded by the Ataxin-3 mediated inhibi-
tion of Parkin autoubiquitination. Parkin, its cognate E2 UbcH7, andTable 1
DUBs discussed. Where available, substrates, functions and additional structural data are n
DUB Res Substrate(s) PDB (notes)
USP DUBs
USP3 520 Histone H2A [137]
Histone H2B [137]
None
USP5/IsoT 858 Unanchored poly-Ub [115] 3IHP (+Ub-ethylamine) [50]
2G45 (ZnF-UBP + Ub) [119]
USP7/HAUSP 1102 p53 [97]
MDM2 [96]
MDMX [98]
FOXO4 [196]
PTEN [197]
Histone H2B [198]
Claspin [199]
UHRF1 [200]
HSV ICP0 [201]
EBV EBNA1 [202]
BMI1 [153]
MEL18 [153]
RING2 [171]
1NB8 (apo USP domain) [49]
1NBF (USP + Ub-aldehyde) [49]
USP8/UBPY 1118 Membrane receptors/
ESCRT cargo [10,172]
GRAIL [203]
STAM2 [179]
NRDP1 [181]
BRUCE [204]
PAR2 [205]
2GFO (apo USP domain) [206]
3N3K (USP domain + speciﬁc in
2A9U (MIT/dimerization domain)
2GWF (Rhodanese domain + NR
USP14 494 Proteasome substrates [33] 2AYN (apo) [51]
2AYO (+ Ub-aldehyde) [51]
USP16/UBP-M 823 Histone H2A [154] 2I50 [168]
USP21 565 Histone H2A [139]
RIP1 [208]
2Y5B (+ linear di-Ub aldehyde)
USP22 525 Histone H2A [141,142]
Histone H2B [141–143]
None
UCH DUBs
UCH-L1/PGP
9.5
223 Proubiquitin? 2ETL (apo) [210]
3KW5 (+Ub-VME) [211]
UCH-L3 230 Proubiquitin? 1UCH (apo) [24]
1XD3 (+Ub-VME) [212]
UCH37/
UCH-L5
329 Proteasome substrates [38] 3A7S (apo UCH domain) [213]
3IHR (apo) [214]
BAP1 729 Histone H2A [215]
HCF-1 [36,37]
OGT [157]
None
OTU DUBs
OTUB1 271 GRAIL [203]
TRAF3 [99]
TRAF6 [99]
P53 [103]
ERα [100]
RhoA [101]
2ZFY (apo) [55]
4DDI (fusion to UbcH5b ~ Ub +
4DHI (worm OTUB1 + UBC13) [1
4DHJ (worm OTUB1 + Ub-aldeh
Ubc13 ~ Ub) [105]
A20 790 RIP1 [63]
TRAF6 [216]
MALT1 [217]
2VFJ (apo OTU domain) [57]
3DKB (apo OTU domain) [61]
3OJ3 (ZnF-4 + Ub) [133]
3OJ4 (ZnF-4 + UbcH5a + Ub) [1
Josephin DUBs
Ataxin-3 364 Misfolded ER proteins
[69,218]
1YZB (NMR, apo Josephin domain
2AGA (NMR, apo Josephin domai
2JRI (NMR, Josephin + Ub + Ub
2KLZ (NMR, UIM domain + Ub)
Ataxin-3 L 355 Undetermined 3O65 (Josephin domain + Ub-chloAtaxin-3 form a tight complex preventing the autoubiquitination of
Parkin and the release of UbcH7 [102]. Interestingly, the inhibition
of autoubiquitination and the formation of a tight complex requireoted.
Cellular role(s) Additional domain(s)
Cell cycle
progression
ZnF-UBP
Ub recycling Novel ZnF-UBP-like domain
ZnF-UBP binds free C-terminus of Ub
UBA-1 forms S3 site
UBA-2 forms S2 site
Cell cycle
progression
Apoptosis
DNA damage
response
Transcription
Immune response
Viral replication
TRAF/Math domain binds p53,
MDM2, EBNA1
5 C-terminal UBL domains, additional
interactions with p53 and MDM2
hibitor) [207]
[206]
DP1) [206]
Endocytosis
Endosome sorting
Cell cycle
progression
MIT/dimerization domain
Rhodanese domain binds NRDP1
Ub recycling UBL domain
Mitotic progression
Transcription
ZnF-UBP binds C-terminus of
Histone H4
[209] Transcription
Signal transduction
Microtubule
dynamics
N-terminus mediates microtubule
and centrosome binding
Transcription ZnF-UBP
Proubiquitin processing?
Ub recycling?
None
Proubiquitin
processing?
Ub recycling?
None
Chain editing
Ub recycling
ULD binds Rpn13 of 19S regulatory
particle ULD binds NRFKB of INO80
Cell cycle progression
Transcription
Hematopoiesis
ULD binds YY1
HBM binds HCF-1
Ub) [104]
05]
yde +
Signal transduction
T-cell anergy
DNA damage response
E2 enzyme inhibition
N-terminal helix binds Ub
33]
Signal transduction
Immune response
7A20-ZnF domains bind poly-Ub
and TAXBP1
ZnF-1 binds RIP1, ZnF-4 binds Ub,
ZnF-5 and -6 bind UbcH5a,
) [72]
n) [67]
) [NP]
[NP]
ERAD
Aggresome
formation
Transcription
UIM1
UIM2 binds VCP
Poly-Q rich
UIM3
roethylamine) [64] Similar to Ataxin-3? UIM1
UIM2
Poly-Q rich
(continued on next page)
Table 1 (continued)
DUB Res Substrate(s) PDB (notes) Cellular role(s) Additional domain(s)
JAMM DUBs
2A-DUB/
MYSM1
828 Histone H2A [140] 2CU7 (SANT domain) [219]
2DCE (SWIRM domain) [219]
Transcription
Hematopoiesis
SANT
SWIRM
RPN11/POH1 310 Proteasome substrates [75,76] 4B4T (yeast Rpn11 within
26S proteasome) [220]
Ub Recycling
Chain editing
C-terminal extension
BRCC36 316 Histone H2A/H2A.x [126]
NLRP3 [127]
None DNA damage
response
Inﬂammatory
response
Coiled-coil
AMSH 424 Membrane receptors/
ESCRT cargo [10,172]
STAM [221]
HRS [221]
None Endosome sorting MIT
Clathrin binding domain
AMSH-LP 436 Undetermined 2ZNR (apo JAMM domain) [82]
2ZNV (JAMM domain + K63 di-Ub) [82]
Similar to AMSH? MIT
CSN5/JAB1 334 SCF E3 ligases [222] 4F7O (apo JAMM domain) [83] Activation of SCF ligases C-terminal extension
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pre-ubiquitinated Parkin or on E2 ~ Ub [102].
Parkin is a Parkinson's disease associated E3 containing a RING-
between-RING (RBR) domain. Recently it has been recognized that
RBR ligases actually use a mechanism characteristic of the HECT-
domain family of ligases, that is they ﬁrst transfer Ub from E2 ~ Ub
to an active site thiol and then pass it on to a protein amino group
[4]. UbcH7, the E2 that works with Parkin, is unable to transfer direct-
ly to an amino group via the usual RING mechanism. Thus, it is likely
that Ataxin-3 inhibits parkin autoubiquitination by intercepting the
Ub from E2 ~ Ub with its own active site thiol and the resulting
DUB thioester intermediate is protected from hydrolysis by the stable
ternary complex.
3.1.4.2. OTUB1. As discussed in Section 3.1.3.2, OTUB1's is highly
speciﬁc for K48-linked poly-Ub and stabilizes its substrates by
disassembling these proteasome-targeting chains. OTUB1 also func-
tions non-catalytically to inhibit K63 ubiquitination of histone H2A
by the E3 RNF168 during the DNA damage response [62]. Depletion
of OTUB1 led to continuous ubiquitination of histone H2A following
ionizing radiation, and overexpression of OTUB1 or the catalytically
inactive mutant both suppressed H2A polyubiquitination [62]. This
non-canonical mode of regulation was also reported when OTUB1
was shown to stabilize and activate p53 independent of catalytic ac-
tivity [103]. Insights into this unusual mode of regulation began
with the identiﬁcation of E2 conjugating enzymes that co-purify
with OTUB1, including Ubc13 an E2 that generates K63 poly-Ub (in
conjunction with the E2 variant UVE1) and functions with RNF168
in the DNA Damage Response (DDR) pathway [62]. OTUB1 was
shown to directly bind Ubc13, preferring to bind the Ub thiolester
Ubc13 intermediate (Ubc13 ~ Ub), and this interaction was stabilized
by OTUB1 N-terminal domain. Similar preferential binding to Ub
charged UbcH5b was shown, and activity assays with E3 enzymes
concluded that OTUB1 functions as an E2 inhibitor, preventing
autoubiquitnation of the E3 TRAF6 [62].
Structures of apo OTUB1 and OTUB1 in complex with the E2s
UbcH5b/UBE2D2 and Ubc13 have also been reported (Fig. 4A). A
UbcH5b(C85S)–OTUB1 fusion protein was generated and reacted with
E1 and Ub to generate a stable E2–Ub oxyester bond [104]. In this struc-
ture the E2 residues that contact OTUB1 are also known tomediate bind-
ing to E3s, thus explaining how binding to the DUB inhibits the E2/E3
interaction. The Ub conjugated to UbcH5b predominately interacts
with OTUB1; one of these interactions is mediated by the N-terminus
of OTUB1 discussed above, which forms an extended helix (Fig. 4B).
The OTU domain also contacts the UbcH5-linked Ub (S1′ site) and posi-
tions K48 towards the catalytic cleft. Unexpectedly a second, free Ubwas
bound to OTUB1 (S1 site) and its C-terminal tail was juxtaposed nearK48 of UbcH5-conjugated Ub within the catalytic cleft [104]. Thus
OTUB1 simultaneously binds to E2-charged Ub and a free Ub, and the ar-
rangement of these two ubiquitins mimics K48 di-Ub. Contemporane-
ously, two additional OTUB1/Ubc13 structures were reported; human
Ubc13 in complexwith C.elegansOTUB1, and humanUbc13 ~ Ub analog
in complex with C.elegans OTUB1/Ub-aldehyde [105] (Fig. 4C). The res-
idues needed for Ubc13 to generate K63 poly-Ub and transfer it to sub-
strates (via binding to UEV1 and RNF168) participate in OTUB1 binding,
displaying amodeof competitive inhibition analogous to that of UbcH5b
[105]. Another notable ﬁnding from this study is that free Ub binding to
OTUB1 (at S1) allosterically regulates the enzymeby increasing its afﬁn-
ity for Ubc13 ~ Ub (at S1′) [105].
3.2. Processing, recycling, and remodeling polyubiquitin chains
A variety of DUB activities are required to initiate and sustain
Ub-dependent processes. These include processing of the primary
gene products to yield Ub, disassembling the polyubiquitin chains to
down regulate signaling and prevent competitive inhibition of Ub re-
ceptors, and recovery of Ub from chains and other inadvertently
trapped Ub derivatives.
3.2.1. UCHL1/L3 — processing pro-Ub and removal of adventitious
Ub derivatives
UCHL1 and UCHL3 are proposed to liberate small molecule nucleo-
philes thatmayhave inadvertently reactedwithUbC-terminal thiolesters
[35]. Because these enzymes can cleave small peptides from the
C-terminus of Ub, they could also function in recycling Ub from incom-
plete proteasomal or lysosomal protein degradation [35]. Another possi-
ble role is the co-translational processing of proubiquitin. In most
organisms, Ub is expressed as a linear polymer, proubiquitin, consisting
of multiple copies of Ub and one or more amino acids appended to the
C-terminus of the ﬁnal Ub. For example, in humans polyubiquitin-C is
expressed as 9 Ub monomers followed by a Val, and polyubiquitin-B as
3 monomers followed by a Cys [106]. It is possible that the smaller UCH
DUBs function in removing these terminal amino acids fromproubiquitin.
While the precise cellular substrate of these enzymes remains
unclear, UCH-L1 is cytosolic, highly expressed in the brain, accounting
for 1–2% of soluble brain protein, and expressed at low levels in ovaries
and testes [107,108]. UCH-L3 is cytosolic and highly expressed in the
heart and in skeletal tissue [109]. UCH-L1 has been linked to neurode-
generative disorders inmice and in humans. Inmice, spontaneous dele-
tion of exons 7 and 8 results in a recessive disorder called gracile axonal
dystrophy (gad) and the accumulation of β-amyloid protein and
ubiquitinated proteins [110]. In humans UCH-L1 is found in neuroﬁbril-
lary tangles of Alzheimer's disease patients [111] and is down regulated
and oxidatively inactivated in brains of Alzheimer's and Parkinson's
Fig. 4. The OTUB1 deubiquitinase binds charged E2s and inhibits their transfer of
ubiquitin to E3. (A) The human OTUB1 structure (PDB 2ZFY) with side chains of the
catalytic triad (C91, H265, and D267) depicted as spheres. The structure was solved
using an OTUB1 deletion lacking the N-terminal 39 residues, which form the N-termi-
nal helix and the S1′ site. (B) The structure of human OTUB1 bound to UbcH5bC85S-Ub
(covalently linked to UbcH5b S85 by an oxyester bond) and free Ub (PDB 4DDI). The E2
UbcH5b and its linked Ub form contacts with the N-terminal helix, and this E2-conju-
gated Ub binds the S1′ site with K48 positioned towards the catalytic triad and the
C-terminus of ubiquitin at the S1 site. (C) The structure of human/worm OTUB1
bound to Ubc13-UbG75C (covalently linked to Ubc13 C87 with dichloroacetone) and
Ub-aldehyde (PDB 4DHJ). The hybrid OTUB1 contains the ﬁrst 45 residues from
human OTUB1 followed by the OTU domain from worm OTUB1. Ub aldehyde is cova-
lently bound at the S1 site. OTUB1 binds both Ub-charged E2s in a similar fashion,
with K48 of the E2-linked Ub positioned towards the active site and the C-terminus
of Ub bound at the S1 site. The binding and arrangement of two ubiquitin molecules
at the S1 and S1′ sites in these two structures mimics OTUB1's natural substrate
K48-linked poly-Ub.
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association and its localization correlates with α-synuclein accumula-
tion and toxicity [113].
3.2.2. USP5/IsoT—recycling polyubiquitin chains
IsoT functions in recycling monomeric Ub by disassembling unan-
chored poly-Ub chains. These unanchored chains are produced from
two sources, proteasomal DUBs that cleave poly-Ub from substrates or
from E2/E3 enzymes that synthesize these chains for conjugation to
substrates. Deletion of yeast IsoT (UBP14) leads to the accumulationof polyubiquitin and inhibition of proteasomal degradation due to com-
petitive inhibition by the accumulated chains. Knockdown of the mam-
malian IsoT (USP5) causes a similar accumulation of polyubiquitin as
well as an increase in the proteasomal substrate p53 [114].
Mechanistic studies on IsoT found it preferred cleaving longer K48
poly-Ub chains (≥4) over shorter chains and linear poly-Ub, and that
it acts as an exopeptidease, cleaving the proximal Ub from unanchored
poly-Ub chains [115–117]. IsoT shows little speciﬁcity for Ub-chain
linkages, as it can hydrolyze tetra-Ub linked through K48, K63, K6 and
K29 [118]. Early studies predicted multiple Ub binding sites;
Ub-aldehyde was shown to slow the dissociation of free Ub, and high
levels of free Ub were capable of inhibiting disassembly of poly-Ub in
a chain dependent manner [115,117]. IsoT contains two Ub-binding
UBA domains inserted within its USP domain, an N-terminal domain,
and a ZnF-UBP domain. A crystal structure of the isolated ZnF-UBP do-
main revealed that IsoT binds Ub or unanchored polyubiquitin chains
by forming extensive contacts with the free C-terminal Gly-Gly motif
[119]. Mutating the C-terminal Gly of Ub to Ala (G76A) or deleting the
di-Gly motif abolishes binding to the ZnF–UBP domain [119]. Thus the
ZnF–UBP domain binds the proximal Ub of a poly-Ub chain in the S1′
site, and subsequent studies, using UBAmutants and quantitative bind-
ing assays, determined UBA-2 forms the S2 site and UBA-1 the S3 site
[120] (Fig. 2C). The crystal structure of the full length enzyme in com-
plex with Ub-ethylamide was recently reported and conﬁrmed the ar-
rangement of the 4 Ub binding sites [50]. However the structure does
not represent a catalytically competent state, as modeling of Ub into
the S1′ ZnF–UBP site found K48 to be ~45 Ǻ from the catalytic Cys of
the S1 site containing Ub-ethylamide. Conformational ﬂexibility within
a disordered loop that tethers the ZnF–UBP domain to the USP domain
likely allows rearrangements that both close this gap and permit the in-
discriminate hydrolysis of various chain linkages. The N-terminal do-
main of IsoT was found to adopt a novel ZnF–UBP-like fold, but it
cannot bind free Ub and lacks conserved Zn2+ coordinating residues
[50].
3.2.3. BRCC36 downregulates DSB signaling by removing K63-linked
polyubiquitin
The DNA damage response (DDR) to double strand breaks (DSB)
leads to the phosphorylation of histone H2A.x at Ser139 by the ATM
and DNA-PKcs kinases [121]. This phosphorylation event results in the
recruitment of MDC1 and the E3 ligases RNF8 and RNF168which assem-
ble K63 poly-Ub chains on H2A.x [122]. This modiﬁcation on H2A.x
serves to both relax chromatin and to create a binding site for the
Rap80 complex, which binds K63 poly-Ub using tandem UIMs and as-
sembles repair complexes containing BRCA1 [122]. BRCC36 is a K63 spe-
ciﬁcmetallo-DUBand core component of theﬁve subunit Rap80 complex
[80,123–125]. BRCC36 functions in the disassembly of K63 poly-Ub on
H2A/H2A.x and termination of RNF8/RNF168 ubiquitination events
[126]. Depletion of BRCC36 led to the accumulation of ubiquitinated
H2A.x following IR, and overexpression of BRCC36 decreases Ub-H2A at
DSBs, an effect dependent on Zn2+ coordinating residues [126]. BRCC36
also functions in a four subunit cytoplasmic complex, BRISC, that shares
similar components of the RAP80 complex [80]. BRCC36 within BRISC
functions in disassembling poly-Ub chains on NLRP3 (but not the proxi-
mal ubiquitin) in response to viral and bacterial infection, promoting
the assembly of the NLRP3 inﬂammasome complex [127].
3.2.4. A20-remodels K63-linked chains to form K48-linked chains and
terminate NFκB signaling
A20 is an OTU DUB that contains a C-terminal extension harboring
7 ZnF domains that endow A20 with E3 Ub ligase activity. A20 is a key
regulator of the immune and inﬂammatory response pathways that
trigger transcriptional activation of NFκB family of transcription fac-
tors. It deubiquitinates components (RIP1, TRAF6, MALT1) in multiple
immune signaling cascades including TNFR1, IL-1R, and TLR4 to down
regulate the NFκB response [128]. In humans mutations within the
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diseases [128]. In response to TNF signaling, K63 poly-ubiquitination
of RIP1 promotes the assembly of a complex that phosphorylates
the NFκB inhibitor IκBα. Phosphorylation of the cytoplasmic NFκB/
IκBα complex results in the proteasomal degradation of IκBα and re-
lease of NFκB to allow its entry into the nucleus and transcriptional
activities. A20 acts directly on RIP1 to disassemble K63 poly-Ub, a
prerequisite for its E3 activity that subsequently polyubiquitinates
RIP with K48 chains to target it to the proteasome for degradation
[63]. Precise details of this mechanism are still poorly understood,
as A20 also binds TAXBP1 and the E3 ligase ITCH, an E3 necessary
for RIP1 ubiquitination and degradation [129]. The E3 activity of
A20 also functions in dampening NFκB signaling by targeting the E2
enzymes UbcH5a and UBC13 for degradation [130]. These E2s func-
tion during different stages of the TLR4 and IL-R1 signaling cascades
to promote NFκB activation by ubiquitination and activation of
TRAF6 (using UBC13) and IKK (using UbcH5a) [131,132]. The E3
ITCH is not required for UBC13 degradation [130], suggesting A20
has intrinsic E3 activity as well as a second E3 activity mediated by
the TAXBP1/ITCH complex.
In vitroA20 shows lowDUBactivity andprefers K48poly-Ub as a sub-
strate over K63 poly-Ub, yet it deubiquitinates K63 poly-ubiquitinated
TRAF6 by clipping at the base of the chain, removing it en bloc [61]. Crys-
tal structures of the A20 OTU domain revealed a minimal catalytic site
that rationalizes its generally weak DUB activity [57,61]. In place of the
conserved catalytic Asp/Asn found in other thiol DUBs, the A20-like
OTU DUBs utilize a nearby Asp/Glu to bind a water molecule which ful-
ﬁlls the role of His-polarization [56,57]. A thorough analysis of the A20
ZnF domains further deﬁned their roles in binding to Ub, E2s, and sub-
strates; ZnF-1 promotes RIP1 binding, ZnF4 binds Ub, and ZnF-5 and -6
bind UbcH5a [133].
3.3. DUBs acting at the level of localization
As suggested by Fig. 1, the regulation of ubiquitination and
deubiquitination is often very dependent on localization. To illustrate
this point we have chosen to discuss the regulation of a single
ubiquitination event, the modiﬁcation of Histone H2A, in a variety of
contexts involved in the structure of chromatin and transcriptional reg-
ulation. Histone H2A was the ﬁrst protein shown to be modiﬁed by Ub
when in 1977 it was found to contain an unusual structure with two
N-termini and a single C-terminus [8]. We now know that in humans
~10% of histone H2A is ubiquitinated at K119, and ~1% of H2B is
ubiquitinated at K120 [134]. H2Aubiquitination at K119was understood
to be the only site of modiﬁcation, but very recently two groups have re-
ported a second site, K13/K15, as the site of ubiquitination by RNF168
during DDR [135,136]. Regulation of H2A and H2B ubiquitination status
plays a role in several nuclear processes in addition to DDR including
transcriptional activation, gene silencing, cell cycle progression, and mi-
tosis. While the precise functions of H2A/H2B ubiquitination in tran-
scription remain largely ambiguous, ubiquitination of H2B is generally
associated with actively transcribed genes and thought to function in
transcriptional initiation,while ubiquitination of H2A is usually associat-
ed with silenced genes, including X-inactivated genes and developmen-
tally regulated genes [20,134]. Ubiquitination of chromatin is one of
several post-translational modiﬁcations to occur on histones, and the
cross-talk between these epigenetic marks collectively orchestrates the
aforementioned processes.
3.3.1. USP7, USP16, and BAP1 are Chromatin-Associated DUBs regulating
HOX genes
There are nine DUBs in humans that have been shown to act upon
ubiquitinated H2A or H2B–USP3, USP7, USP16, USP21, USP22, USP44,
2A-DUB, BRCC36 and BAP1 (see Table 1). USP3 was identiﬁed in HeLa
chromatin extracts and its depletion elevates the levels of ubiquitinated
H2A and H2B, delays S-phase progression and induces the DNA damageresponse [137]. USP21 deubiquitinates H2A during hepatocyte regener-
ation to activate gene transcription, and it localizes to centrosomes en-
suring propermicrotubule dynamics [138,139]. 2A-DUB, a JAMM family
DUB, was found to deubiquitinate H2A and positively regulate tran-
scription of androgen receptor regulated genes in concert with the his-
tone acetylase p/CAF complex [140]. USP22 is a component of the SAGA
transcriptional coactivator complex and can deubiquitinate H2A and
H2B [141–143]. USP44 negatively regulates H2B ubiquitination during
embryonic stem cell development [144]. Histone deubiquitination has
been the subject of recent reviews [20,134,145], and here we highlight
three DUBs, USP7, USP16, and BAP1, that function in polycomb group
(PcG) complexes and modulate transcription of PcG target genes.
The ubiquitination of H2A-K119 by the E3 ligase RING2 (Ring1b) and
its coactivator BMI1 has an established role in transcriptional repression
of homeotic genes and in X chromosome inactivation [146–148]. Re-
pression of these genes is accomplished by a group of polycomb group
proteins (PcG) that were identiﬁed in Drosophila genetic screens as nec-
essary to silence the expression of HOX genes and prevent homeotic
transformations. PcG proteins assemble to form three distinct com-
plexes in Drosophila, PhoRC, PRC1 and PRC2 [149–151]. PhoRC directly
binds to polycomb response elements (PREs) within DNA and recruits
PRC2 which contains H3-K27 trimethylase activity, and PRC1, which
contains the H2A-K119 Ub E3 ligase complex Sce/Psc (RING2 and
BMI1 in humans). An expansion of the PcG proteins in humans has led
to multiple orthologs of their ﬂy counterparts; for example, the PRC1
E3 ligase proteins Sce has two human paralogs (RING1 and RING2)
and Psc has three (BMI1, MEL18, and NSPC1) [150]. Deubiquitination
of H2A-K119 at PcG-regulated genes in ﬂies has been attributed to a
UCHDUB called Calypso, the homolog of human BAP1, which associates
with the PRC2 complex by binding to the Asx protein [152]. In humans
USP7 and USP11 co-purify with PRC1 proteins and indirectly regulate
expression of PcG target genes [153]. Another DUB, USP16, has been
shown to regulate the expression of human HOXD10 [154], but its re-
cruitment to PcG complexes is less understood.
3.3.1.1. BAP1. In ﬂies, chromatin-IP (ChIP) studies found the Calypso/Asx
complex co-localizedwith PcGproteins Pho (of PhoRC) and Ph (of PRC1)
at the PREs of several PcG protein targets including HOX genes [152]. Ex-
amination of the HOXUbx gene in cells where expression is either active
or inactive found that Calypso/Asx bound to the Ubx PRE in both
cases [152]. Loss of Calypso in larval imaginal discs,whereUbx is normal-
ly repressed, led to activation of Ubx expression and this was rescued by
transgene expression ofwild type Calypso but not the active site Cysmu-
tant. Thus the localization of Calypso/Asx alone does not dictatewhether
Ubx is activated or repressed, but loss of Calypso leads to transcriptional
activation. Loss of Asx in ﬂies led to an increase inUb-H2A levelswithout
inﬂuencing other chromatinmarks (H3K4me3, H3K27me3), and assays
using puriﬁed proteins found Asx stimulates Calypso activity towards
Ub-AMC, and that Asx/Calypso and the human orthologs BAP1/ASXL1
deubiquitinate H2A but not H2B in reconstituted nucleosomes [152].
The inﬂuence of BAP1 and ASXL1 on HOX gene expression has also
been examined by ChIP in human hematopoietic cells. In these studies,
depletion of BAP1 does not inﬂuence expression from the HoxA gene
cluster, however depletion of ASXL1 reduces H3K27me3 levels and the
presence of PRC2 components while enhancing H3K4me3 levels,
Ub-H2A levels, and transcription of HoxA genes [155]. Taken together,
these results show that the BAP1/ASXL1 complex in both humans and
ﬂies functions in repressing Hox gene expression, although the precise
temporal epigenetic modiﬁcations differ between organisms.
BAP1 is believed to have gained additional functions in eukaryotes be-
cause, unlike Calypso, it contains an HCF-1 binding motif (HBM) known
to mediate BAP1 binding to HCF-1 in mice and humans [36,37]. HCF-1
is a transcriptional regulator that can bind a host of transcription factors
as well as activating and repressing chromatin-modifying complexes
[156]. ChIP studies in mice have found that BAP1 and HCF-1 co-localize
to 3800 gene promoters, though it is not known whether ASXL1 is also
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be regulated by BAP1 suggests it plays critical role in the cell, and this is
proving to be true as mutations within the BAP1 gene have been linked
to a number of cancers, including lung adenocarcinoma, uveal melano-
ma, clear cell renal cell carcinomas, malignant mesothelioma, and novel
melanocytic tumors [46,158–161]. Germline mutations to BAP1 predis-
poses to some of the aforementioned cancers [162–165]. BAP1 knockout
mice are embryonic-lethal, and inducible knockout of BAP1 led to mye-
loid transformations characteristic of human chronic myelocytic leuke-
mia, a disease recently linked to ASXL1mutations in humans [155,157].
3.3.1.2. USP16 (Ubp-M). In a search for DUBs that could deubiquitinate
H2A, fractionation of HeLa cell H2A DUB activity led to the isolation of
USP16 [154]. USP16 is speciﬁc for Ub-H2A, as it deubiquitinates nucleo-
somal Ub-H2A in vitro and its depletion in cells elevates Ub-H2A levels
without inﬂuencing Ub-H2B [154]. Examination of the HOXD10 gene
expression found depletion of USP16 led to an increase in its expression,
and this defect was rescued by re-expression of the wild type enzyme,
but not the active site Cys mutant. ChIP studies on HOXD10 binding of
USP16 and the BMI1 subunit of PRC1 found both proteins are localized
to the HOXD10 promoter, yet H2A was not ubiquitinated unless USP16
was depleted. Because BMI1 promoter occupancy was unaffected in
USP16-depleted cells, these ﬁnding suggest DUB activity counteracts
PRC1-mediated ubiquitination to maintain a repressed state of tran-
scription [154]. USP16 was also identiﬁed in a mitotic phosphoprotein
screen where it was shown to be phosphorylated in prometaphase
and metaphase, to bind mitotic chromosomes and to deubiquitinate
isolated chromatin [166]. USP16 regulates chromatin condensation dur-
ing mitosis by deubiquitinating H2A, an activity that precedes H3-S10
phosphorylation by the Aurora B kinase [154], a hallmark of condensed
metaphase chromosomes [167]. Intriguingly, USP16 contains an
N-terminal ZnF-UBP domain known to recognize the C-terminal resi-
dues of unanchored Ub (-RLRGG) [119,168]. This is an unexpected fea-
ture for an enzyme that doesn't involve acting on a free Ub chain.
However, a recent study has found that ZnF-UBP domains can bind
C-terminal diglycine sequences present in other proteins with similar
afﬁnity to Ub, and that USP16 binds favorably to such a motif present
in histone H4 (-YGFGG) [169]. USP16 was shown to pull-down recom-
binantH3/H4 tetramer, suggesting it is recruited to its targetH2A by the
Znf-UBP–histone H4 interaction. In support of this ﬁnding, a USP3
ZnF-UBP domain mutation in a conserved histidine that coordinates
Zn2+ abolished its ability to IP histones H2A and H2B [137].
3.3.1.3. USP7/HAUSP. Puriﬁcation of the Psc orthologs BMI1 and MEL18
identiﬁed several PRC1 components along with two DUBs, USP7 and
USP11. Pull-downs with recombinant proteins found both DUBs are ca-
pable of directly associating with other PRC1 members and each other
suggesting they bind multiple proteins within the PRC1 complex. Exam-
ination of the PRC1-regulated INK4a locus found depletion of both USP7
and USP11 resulted in expression of p16INK4a at the transcript and pro-
tein level, and decreased binding of PRC1 members at the INK4a locus
as assessed by ChIP. Though recombinant USP7 was capable of
deubiquitinating H2A in nucleosomes, its depletion had little effect on
cellular Ub-H2A or Ub-H2B levels, but did destabilize BMI1 and MEL18
protein levels [153]. Thus these DUBs inﬂuence expression from
PcG-regulated promoters by stabilizing PRC1 components rather than di-
rectly acting on Ub-H2A. Although overexpression or depletion of USP7
had no effects on Ub-H2A or Ub-H2B levels in this study, USP7 has
been shown to shown to form a complex with the Epstein-Barr virus
(EBV) protein EBNA1and humanGMP synthase that deubiquitinates his-
tone H2B leading to expression of EBV genes [170]. USP7 was also found
to associate with and deubiquitinate the PRC1 E3 ligase RING2, and this
activity functions to stabilize RING2. USP7 was indiscriminate towards
chain types, cleaving proteasome-targeting K48 chains catalyzed by
the E3 E6AP, and branched K6-, K27-, and K48 chains catalyzed by
auto-ubiquitination [171].3.4. Vectoral processes
Because of the spatial distribution of E3s and DUBs, and the exis-
tence of numerous ubiquitin receptors, this modiﬁcation offers an
ideal system for regulating vectoral processes that result in transport
of a protein from one part of a cell to another. A classic example is in
the endocytic pathwaywhere transport and degradation of cargo pro-
teins depends on ubiquitination at the cell surface, ubiquitin receptor
binding in early endosomes, and deubiquitination at the late endo-
some [10,172]. A variation of this pathway is also important in viral
budding [173], autophagy [174] and cytokinesis [175].
3.4.1. Sorting of proteins to the vacuole/lysosome
A variety of cell surface receptors, especially the receptor tyrosine
kinases such as EGFR, are ubiquitinated by E3 ligases such as the on-
cogene c-Cbl in response to receptor engagement, and this Ub is used
as a sorting tag to direct the protein through the endocytic pathway
to the lysosome for degradation [10,176]. Monoubiquitination and
K63-linked polyubiquitination are most often observed. A number
of endosomal sorting complexes required for transport (ESCRTs) con-
taining Ub-binding domains are thought to ferry the ubiquitinated
cargo to the multivesicular body (MVB) where it is internalized be-
fore the MVB fuses with the lysosome [176]. This Ub must be re-
moved from the cargo for efﬁcient internalization by the MVB. The
timing of deubiquitination is critical; if it occurs early then the recep-
tor can be recycled to the cell surface, while failure to remove it can
consume Ub and slow lysosomal degradation [10,176].
3.4.1.1. USP8 and AMSH regulate endocytosis and lysosomal degradation
of endocytic cargo. Two DUBs, USP8 and AMSH, have been implicated in
this pathway based on genetic and biochemical evidence. Both bind to
the STAM subunit of ESCRT-0 at the sorting endosome and to CHMPS
components of ESCRT-III during formation of the MVB [10,172]. AMSH
exhibits speciﬁcity for K63-linked chains while USP8 can cleave most
types of poly-Ub [81,177]. A precise deﬁnition of the roles of these two
DUBs is complicated by the fact that their effects on endocytosis are de-
pendent on the identity of the substrate and ubiquitination can occur at
several points in the cargo's journey. Nevertheless, we can generalize
that AMSH probably counteracts the activity of membrane localized E3
ligases and enhances recycling of the receptor, as well as inhibiting
binding of Vps4 to ESCRT-III, resulting in failure to dissociate ESCRT-III
complex necessary for sorting [10]. Endocytic defects observed upon
loss of USP8 are believed to primarily impact the ESCRT-0 complex,
however misregulated receptor internalization has also been observed.
USP8 depletion results in enlarged and aberrant endosomes that contain
elevated levels of ubiquitinated proteins, including the sorting protein
Eps15, and decreased levels of STAM2 and Hrs [10,178–180]. USP8
deubiquitinates STAM, preventing its degradation by the proteasome
[179], and Nrdp1, an E3 required for the lysosomal degradation of
EGFR family members ErbB3 and ErbB4 [181].
3.4.1.2. Ataxin3— Crosstalk between proteasomal and lysosomal autophagy
pathways. In addition to endocytosis, substrates can be targeted to the
lysosome by formation of autophagic vesicles. Autophagy proceeds by
formation of a double-membrane vesicle, often around a cellular organ-
elle or deposit, and then fusion with the lysosome. For many years it
was assumed that proteasomal and lysosomal degradation were dis-
tinct unrelated pathways. However, there is now signiﬁcant evidence
that the two interact and that ubiquitin-dependent events are impor-
tant in each [182]. Impairment of each upregulates the other, both uti-
lize polyubiquitin signals (K63 for autophagy and K48 for proteasomal
degradation), and many substrates seem to be degraded by both path-
ways. Further, the p62/sequestosome polyubiquitin binding protein
plays a role in delivering substrates to each process [183].
The best understood connection between these pathways is seen
when misfolded proteins accumulate in the cell, especially disease-
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Lateral Sclerosis, Alzheimer, Parkinson, and Huntington diseases [184].
Aggregated proteins can be refolded by chaperones, cleared by the
proteasomeor autophagy or accumulated at themicrotubule organizing
center in a large inclusion body called the aggresome. Formation of the
aggresome is thought to sequester the aggregates in a non-lethal form
[185] and the balance between these pathways probably depends on
DUBs that can remodel, remove or edit polyubiquitin chains. The
Ataxin-3 DUB associateswith parkin, HDAC6 and other aggresome com-
ponents and its activity enhances aggresome formation by misfolded
superoxide dismutase [186] and the cystic ﬁbrosis transmembrane reg-
ulator [187]. It is hypothesized that Ataxin-3 trims K63-linked chains
from the misfolded ubiquitinated proteins and enhances the rate of
aggresome formation [187].3.5. Proteasome bound DUBs
The 26S proteasome is an ATP-dependent, multi-subunit protease
that primarily functions to degrade poly-ubiquitinated proteins. It can
be subdivided into two complexes, the 20S core particle (CP) and the
19S regulatory particle (RP). The 28 subunit 20S CP is formed by four
heptameric rings that stack to form a barrel-like structure enclosing
three protease sites within its interior lumen. Access to the 20S
lumen is regulated by the ATP-driven 19S RP which opens a translo-
cation channel, unfolds and directs substrates into the CP interior.
The 19S regulatory particle (19 subunits in yeast) also functions in
the recognition and deubiquitination of proteasome substrates. In
humans three DUBs from different families, UCH37/UCH-L5 (UCH),
USP14 (USP), and POH1/RPN11 (JAMM/MPN+), associate with the
proteasomal 19S RP. These enzymes are well conserved in eukaryotes
with the exception of S. cerevisiae which lacks a UCH37 homolog
[188]. They differ in several aspects with regard to their necessity,
role, and catalytic mechanism. Of the three, only RPN11 is an essen-
tial, stoichiometric component, while UCH37 and USP14 transiently
associate and co-purify with proteasomes to different extents in dif-
ferent organisms [41,189]. A separate review in this issue covers
this topic in much more detail (Finley, this volume).3.5.1. RPN11 removes poly-Ub to facilitate coupled translocation
and proteolysis
One function of the proteasome-associated DUBs is to remove the
poly-Ub chain from substrates prior to completing degradation. This ac-
tivity serves to prevent undesired degradation of Ub, but also facilitates
unfolding and translocation of the substrate through the small pore at
the end of the 20S protease. In the absence of these DUB activities, the
proteasome must unfold both Ub and the substrate, translocating both
polypeptides into the CP lumen [188]. This signiﬁcantly slows degrada-
tion of the substrate and results in the proteolytic loss of Ub. Conversely,
if the Ub tag is removed before substrate is engaged by the protease,
degradation may be incomplete or fail entirely due to dissociation of
the substrate.
RPN11 is the DUB largely responsible for removing poly-Ub from
substrate, although USP14 may also contribute since Ub levels drop
in its absence [189–191]. The metalloprotease activity of RPN11
was ﬁrst noticed when treatment of proteasomes with Ub-aldehyde
and Ub-VS failed to inhibit degradation of model substrates [75,76].
RPN11 acts as an endopeptidase, cleaving poly-Ub chains en bloc from
substrates, and its activity within proteasomes is dependent on ATP-
hydrolysis and intact proteasomes [75,76]. Thus RPN11 functions after
the proteasome has engaged the substrate and is committed to proteol-
ysis, a mechanism that prevents dissociation of the deubiquitinated sub-
strate and averted degradation. RPN11 is essential for viability in yeast
[192], and its depletion in HeLa markedly elevates cellular poly-Ub
levels, impairs proteasome assembly, and inhibits cell growth [189].3.5.2. All three proteasomal DUBs play a role in chain editing to assure
ﬁdelity of proteolysis
The K63-linked polyubiquitin chain is not an efﬁcient degradation
signal, in spite of the fact that it is efﬁciently bound by the proteasome,
RPN11 displays highly speciﬁc K63 poly-Ub endopeptidase activity, as
puriﬁed 19S particles treated with NEM are capable of cleaving K63
isopeptide bonds in di-Ub and in a mixed K48/K63 tetra-Ub chain
[80]. As substrates bearing K63 poly-Ub most often are not destined
for proteasomal degradation, RPN11 could contribute a “proof reading”
function by disassembling K63-linkages and preventing degradation of
substrates with this tag.
UCH37 (and possibly USP14) can act as ATP-independent exopepti-
dases, trimming distal Ub progressively from a substrate-anchored
poly-Ub chain [38]. If the polyubiquitin chain is long enough, it can re-
main bound until the substrate is productively engaged and then re-
moved by RPN11 during normal proteolysis the proteasome. If
translocation and proteolysis stalls, the abortive degradation intermedi-
ate needs to be cleared and this trimming will continue to shorten the
chain. Substrates that have short poly-Ub chains have a weaker afﬁnity
for the proteasome [193] and are more likely to be released from the
proteasome rather than degraded. UCH37 associates with the 19S regu-
latory particle via interaction with ADRM1/hRPN13, and that this inter-
action requires a KEKE motif within the UCH37 C-terminal extension
[42–44]. The C-terminal extension holds UCH37 in an inactive state,
and its deletion or engagementwith hRPN13 stimulates Ub-AMChydro-
lysis [42,43]. UCH37 is also a component of the INO80 chromatin remod-
eling complex, where its C-terminal extension mediates binding to the
INO80 subunit NFRKB [41]. When bound to INO80, or NFRKB alone,
UCH37 is inactive towards Ub-AMC; this inhibition is relieved by
co-associating with hRPN13 or puriﬁed proteasomes [41]. UCH37 is
more abundant in proteasomes from bovine blood compared to HeLa
cells, and its high prevalence in HeLa INO80 complexes has suggested
it recruits UCH37-less proteasomes to INO80 to degrade yet-to-be iden-
tiﬁed chromatin targets [41].
USP14, and its yeast ortholog UBP6, require an N-terminal Ub-like
(Ubl) domain for associationwith the 19S particle (to the RPN1 subunit)
and their activity towards Ub-AMC is stimulated 300–800-foldwhen as-
sociatedwith proteasomes [191,194]. Deletion of yeast UBP6 results in a
Ub-depletion phenotype, probably from a failure to remove short
polyubiquitin chains from bound substrates and their subsequent deg-
radation by theproteasome. In yeast, UBP6 delays proteasomal degrada-
tion of cyclin B, and this delay requires an intact Ubl domain and
proteasomal association. Intriguingly, the degradation delay is also ob-
served in the absence of a catalytic cysteine, attributed to a non-
catalytic mechanism of RPN11 inhibition [195].
Finally, it should be noted that these observations suggest a com-
plex coupling and interplay between and among the catalytic particle,
the 19S regulatory complex, and these three DUBs. These interactions
are much more completely discussed elsewhere in this issue (Finley,
this volume).
4. Perspective
Ubiquitin-dependent processes are crucial to all cellular functions.
The assembly of a Ub or poly-Ub tag is a targeting signal that regulates
activity, localization, protein–protein interactions and half-life. Several
hundred ubiquitin ligases and nearly a hundred deubiquitinating en-
zymes control these modiﬁcations. These enzymes are temporally and
spatially controlled and most often act as part of multi-protein com-
plexes. Thus, there has beenmuch interest in these pathways as drug tar-
gets. This survey of DUB action in the proteolysis pathway highlights
important problems that must be overcome to achieve the necessary
speciﬁcity of drug action. A major challenge is designing drugs that will
interfere with nearly a thousand enzymes that all act by a handful of
chemical mechanisms. Another is the fact that a single DUB can have
many substrates and a single substrate can be the target of several
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nase/phosphatase regulated pathways and those enzymes have proven
to be amenable targets in treating important pathologies.References
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